These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22267755)

  • 21. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
    Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
    Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
    Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
    Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
    Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
    J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation.
    Sato S; Motoi N; Hiramatsu M; Miyauchi E; Ono H; Saito Y; Nagano H; Ninomiya H; Inamura K; Uehara H; Mun M; Sakao Y; Okumura S; Tsuchida M; Ishikawa Y
    Am J Surg Pathol; 2015 Jul; 39(7):912-21. PubMed ID: 25970685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.
    Han C; Ma J; Zhao J; Zhou Y; Jing W; Zou H
    Cancer Invest; 2011 Nov; 29(9):626-34. PubMed ID: 22011285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
    Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
    Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.